Immunoprecise Antibodies Ltd Stock Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 89.06M 63.93M 55.4M 51.87M 47.32M 6.1B 90.55M 608M 238M 3.05B 240M 235M 10.18B | P/E 2027 * |
-6.12x | P/E 2028 * | -8x |
|---|---|---|---|---|---|
| Enterprise Value | 89.06M 63.93M 55.4M 51.87M 47.32M 6.1B 90.55M 608M 238M 3.05B 240M 235M 10.18B | EV / Sales 2027 * |
4.4x | EV / Sales 2028 * | 3.58x |
| Free-Float |
90.86% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/2018 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 20/10/2025 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 24/05/2018 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 07/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 63.9M | |
| -1.37% | +4.78% | +45.99% | -1.23% | 80.69B | |
| +2.55% | +13.07% | +2.40% | +30.48% | 51.22B | |
| +0.49% | +2.17% | +22.60% | +177.89% | 49.58B | |
| +2.87% | +11.29% | -46.98% | -47.72% | 45.5B | |
| -1.56% | -2.19% | +59.29% | -25.50% | 30.6B | |
| -0.39% | +0.39% | +52.89% | +83.63% | 24.64B | |
| +1.27% | +6.28% | +137.81% | -40.32% | 23.88B | |
| -1.80% | +11.10% | +4.71% | +196.74% | 21.59B | |
| -5.89% | +34.09% | -0.99% | +792.56% | 17.09B | |
| Average | -0.80% | +182.05% | +30.86% | +129.61% | 38.31B | |
| Weighted average by Cap. | +0.17% | +270.79% | +27.00% | +76.05% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 20.24M 14.53M 12.59M 11.79M 10.76M 1.39B 20.59M 138M 54.17M 694M 54.57M 53.38M 2.31B | 24.9M 17.87M 15.49M 14.5M 13.23M 1.7B 25.32M 170M 66.61M 853M 67.11M 65.65M 2.85B |
| Net income | -14.81M -10.63M -9.22M -8.63M -7.87M -1.01B -15.06M -101M -39.63M -508M -39.93M -39.06M -1.69B | -11.81M -8.47M -7.34M -6.88M -6.27M -808M -12M -80.62M -31.59M -405M -31.82M -31.13M -1.35B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
